Polygenic Risk Scores for Subtyping of Schizophrenia
Table 2
Symptom count changes between the baseline and the end of Phase I trial.
All subjects
Class I
Class II
Class III
Class IV
Class V
Total symptom
Mean Diff
4.17
5.47
3.90
1.12
4.89
3.41
95% CI
2.59-5.75
2.76-8.19
0.78-7.03
−3.34-5.58
−0.12-9.90
−0.32-7.14
5.17
3.98
2.48
3.18
1.97
1.82
435
171
81
56
44
79
3.50E-07
1.02E-04
0.0151
0.6160
0.0557
0.0725
Positive symptom
Mean Diff
1.18
1.26
1.02
0.82
1.60
1.20
95% CI
0.63-1.73
0.31-2.22
0.00-2.05
−0.69-2.34
−0.22-3.42
−0.10-2.50
4.24
2.61
2.00
1.09
1.77
1.83
435
171
81
56
44
79
2.78E-05
9.90E-03
0.0492
0.2801
0.0839
0.0707
Negative symptom
Mean Diff
0.93
1.36
0.65
−0.63
2.18
0.73
95% CI
0.39-1.48
0.47-2.25
−0.54-1.83
−2.32-1.05
0.53-3.82
−0.49-1.94
3.38
3.03
1.08
−0.75
2.65
1.19
435
171
81
56
44
79
7.94E-04
2.81E-03
0.2817
0.4556
0.0111
0.2382
Mean Diff: mean difference between the baseline and at the end of Phase I trial; 95% CI: 95% confidence interval; t: test value; df: degree of freedom; values ≤0.05 were highlighted by bold.
